SHANGHAI, Jan. 7, 2025 /PRNewswire/ — Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the U.S. Food and Drug Administration (FDA) has…Original Article
U.S. FDA Granted Priority Review to Dizal’s Sunvozertinib New Drug Application
